Clinical trials
Atherosclerosis trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Recruiting | 8 |
| Unknown status | 8 |
| Active, not recruiting | 6 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Sao Paulo | 8 |
| University of Sao Paulo General Hospital | 7 |
| Eli Lilly and Company | 4 |
| Amgen | 3 |
| AstraZeneca | 3 |
| GlaxoSmithKline | 3 |
| InCor Heart Institute | 3 |
| Instituto de Cardiologia do Rio Grande do Sul | 3 |
| Novartis Pharmaceuticals | 3 |
| CSL Behring | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 52 |
| Coronary Artery Disease | 15 |
| Cardiovascular Diseases | 14 |
| Coronary Disease | 7 |
| Inflammation | 7 |
| Heart Diseases | 6 |
| Peripheral Arterial Disease | 5 |
| Acute Coronary Syndrome | 4 |
| Hypercholesterolemia | 4 |
| Dyslipidemias | 3 |
Trials
Showing 26 to 50 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.